Medtronic has acquired Arterial Vascular Engineering Inc., capping a string of large, impressive deals that should help build major businesses in important new areas. With the AVE deal, Medtronic has in the last year alone spent almost $8 billlion to acquire five companies.
As they say in New York, when the going gets tough, the tough go shopping. Over the past several years, Medtronic Inc. had quietly stood back while each of several cardiovascular device rivals grabbed headlines with high-profile acquisitions. First it was Johnson & Johnson with its hostile bid for Cordis Corp. [See Deal].
Medtronic hasn't been idle exactly. But the deals it did—for Target rival Micro Interventional Systems Inc. for example [See Deal].
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
